Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated February 6, 2024. The report discloses the existence of an equity offering program established via a Sales Agreement with Jefferies LLC, originally entered into on April 26, 2023. The Company is a foreign private issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The document focuses exclusively on the terms of the equity offering program.
- Aggregate Offering Price: Up to $75.0 million in American Depositary Shares (ADSs).
- Commission Rate: 3.0% of the gross sales price per ADS sold.
- Escrow Arrangements: None.
Material Changes
This filing does not report material changes in financial results or operations compared to a prior period. It serves as a disclosure regarding the ongoing availability of the "at the market" offering program established in April 2023. The Company retains the discretion to sell ADSs from time to time or not at all.
Guidance, Outlook, and Risks
Offering Structure: Sales may be conducted as "at the market" offerings or in negotiated transactions with Company consent. Jefferies LLC acts as the sales agent and is not obligated to sell a specific number of securities but will use commercially reasonable efforts.
Termination Terms: The Sales Agreement terminates upon the sale of all ADSs or earlier if either party provides four days' prior notice.
Risks and Contingencies: The Company has agreed to provide indemnification and contribution to Jefferies regarding certain liabilities under the Securities Act and the Securities Exchange Act of 1934. The filing explicitly states it does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the current number of ADSs sold under the $75.0 million program since April 26, 2023, by reviewing subsequent filings.
- Confirm the Company's current cash position and liquidity needs to assess the likelihood of utilizing the remaining capacity of the offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific conditions regarding pricing and market windows.
- Monitor for any termination notices from either the Company or Jefferies LLC.